Greenlane Hldgs 株価情報 (NASDAQ: GNLN)

最新ニュース Greenlane Hldgs (NASDAQ:GNLN) 株価情報

Greenlane Hldgs

Greenlane Holdings Inc is a platform for the development and distribution of premium cannabis accessories, vape devices, and lifestyle products. It provides a wide array of consumer ancillary products and industrial ancillary products to thousands of cannabis producers, processors, brands, and retailers (Cannabis Operators). In addition, it serves specialty retailers, smoke shops, head shops, convenience stores, and consumers directly through its proprietary web stores and large online marketplaces such as Amazon. Its geographical segment includes the United States, Canada, and Europe. It derives a majority of revenue from the United States.

Greenlane Holdings, Inc. - Class A Common Stock

Greenlane Holdings Inc

U.S. President Donald Trump signed an executive order Thursday to jumpstart the U.S. deep-sea mining industry. Trump seeks to secure domestic access to critical resources through this initiative and reduce America's dependence on foreign supply chains for <a target="_blank" href="https://www.benzinga.com/markets/commodities" rel="noreferrer noopener">increasingly important commodities</a>.
"The United States has a core national security and economic interest in maintaining leadership in deep-sea science and technology and seabed mineral resources," Trump <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/04/unleashing-americas-offshore-critical-minerals-and-resources/" rel="noreferrer noopener">stated</a> in the order, signed privately on Thursday.
The directive empowers agencies to expedite permits for mining on the U.S. Outer Continental Shelf and in international waters under the Deep Seabed Hard Mineral Resources Act of 1980. It also mandates reports and strategies across agencies to identify domestic and global seabed mineral extraction and processing opportunities.
Trump's decision aligns with growing pressure from mining companies and U.S. allies to challenge China's global critical minerals market dominance. Vast fields of polymetallic nodules — rock-like deposits rich in nickel, manganese, and copper — are scattered across the seafloor, especially in the Pacific Ocean.
Yet the international community remains divided. The International Seabed Authority (ISA), formed under the United Nations Convention on the Law of the Sea, has yet to finalize regulations for commercial deep-sea mining. Last month's (March) convention in Kingston, Jamaica, failed to achieve a breakthrough, and the organization has yet to finalize commercial <a target="_blank" href="https://deep-sea-conservation.org/media-release-deep-sea-mining-company-plans-met-with-global-pushback-as-international-seabed-authority-meeting-concludes/" rel="noreferrer noopener">deep-sea mining regulations</a>.&nbsp;
The U.S. is not a signatory to the convention but recognizes ISA's role in overseeing activities in international waters. A lack of consensus over permissible noise, dust, and sediment disturbance has delayed the rulemaking process for over a decade.
Environmental advocates have fiercely criticized the move. Oceanographic Magazine called the decision "an environmental disaster in the making," <a target="_blank" href="https://oceanographicmagazine.com/news/trumps-deep-seabed-mining-move-an-environmental-disaster/" rel="noreferrer noopener">stating</a> that the order would "open one of Earth's most fragile and least understood ecosystems to reckless industrial exploitation."
"The deep ocean belongs to everyone, and protecting it is humanity's global duty. The sea floor environment is not a platform for ‘America First' extraction," added Emily Jeffers, a senior attorney at the Center for Biological Diversity.
Despite the uncertainty, companies are already racing ahead. The Metals Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMC#NYSE">TMC</a>) <a target="_blank" href="https://www.benzinga.com/government/regulations/25/03/44543787/tmc-pushes-for-the-fastest-pathway-to-commercial-production-despite-environmental-risks" rel="noreferrer noopener">announced last month</a> it would seek a license through the U.S. government, bypassing ISA. Shares of TMC soared more than 44%, closing at $3.69 after yesterday's announcement.
Odyssey Marine Exploration (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>), another deep-sea player, saw its stock <a target="_blank" href="https://www.benzinga.com/news/25/04/44990450/why-odyssey-marine-exploration-omex-stock-is-exploding-higher" rel="noreferrer noopener">more than double</a>, closing at $0.85. The company specializes in underwater mineral exploration and has been discussing potential licensing opportunities with the National Oceanic and Atmospheric Administration.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44994275/gold-now-worth-100x-more-than-silver-analysts-say-its-time-to-buy-the-underdog" target="_blank" rel="noreferrer noopener">Gold Now Worth 100x More Than Silver: Analysts Say It's Time To Buy The Underdog</a></li>
</ul>
Photo by DenisSergeeich via Shutterstock

Equities

Government

News

Regulations

Commodities

Politics

Legal

Markets

MTRN

OMEX

USAR

Sea Mining Stocks Soar As Trump Signs Executive Order To Jumpstart Sector

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) reported quarterly earnings of $2.46 per share which beat the analyst consensus estimate of $2.38 by 3.36 percent. This is a 6.49 percent increase over earnings of $2.31 per share from the same period last year. The company reported quarterly sales of $13.34 billion which beat the analyst consensus estimate of $12.92 billion by 3.25 percent. This is a 8.39 percent increase over sales of $12.31 billion the same period last year.

Earnings

Earnings Beats

ABBV

AbbVie Q1 Adj. EPS $2.46 Beats $2.38 Estimate, Sales $13.34B Beat $12.92B Estimate

Two million dollars might sound like an iron-clad nest egg, but where you spend your golden years can make it evaporate or endure for decades.
What Happened: A new GOBankingRates <a href="https://www.gobankingrates.com/retirement/planning/how-long-2-million-will-last-in-retirement-in-every-state/">study</a> finds the same bankroll plus average Social Security checks would last 72 years in West Virginia, yet only 23 years in Hawaii — a three-fold swing driven largely by housing costs.
Analysts tallied typical retiree expenses for groceries, health care, transportation, utilities and shelter using the Bureau of Labor Statistics' 2023 Consumer Expenditure Survey, then adjusted those figures with the Missouri Economic Research and Information Center's cost-of-living index for each state.
Low-cost Appalachia dominates the longevity leaderboard. After West Virginia, Kansas stretches $2 million for 69 years, while Mississippi, Oklahoma and Alabama hover between 66 and 68 years. Retirees in these states can expect post-Social-Security budgets near $30,000 a year, leaving plenty of cushion even with modest investment returns.
See also: <a href="https://www.benzinga.com/general/25/04/45004194/dave-ramsey-calls-social-security-a-4-return-but-this-wealth-expert-says-thats-a-dangerous-oversimplification-that-could-cost-thousands">Dave Ramsey Calls Social Security A &#8216;-4% Return&#8217; —But This Wealth Expert Says That&#8217;s A Dangerous Oversimplification That Could Cost Thousands</a>
At the other extreme, three states with sky-high real-estate tabs would burn through the same savings in roughly 30 years or less. Hawaii's retirees face annual outlays of nearly $88,000 after Social Security. California and Massachusetts trail close behind at about $64,000 and $65,000, respectively, shortening the portfolio's lifespan to 31 years.
The Bottom Line: The gap shows how sharply shelter costs skew retirement math. In coastal states with dense urban centers, housing alone can run $30,000 more per year than in the heartland, the report shows.
Although hitting $2 million is a reach for most — just <a href="https://www.ebri.org/retirement/content/the-status-of-american-families%27-accumulations-in-individual-account-retirement-plans--an-analysis-of-the-2022-survey-of-consumer-finances">1.8 percent of households</a> have amassed that much, according to the Employee Benefit Research Institute — the analysis suggests even a <a href="https://www.benzinga.com/personal-finance/24/11/42070971/suze-orman-warns-3-million-isnt-enough-for-retirement-even-at-a-mere-3-withdrawal-rate-she-says-you-need-10-million-or-more">seven-figure balance can be fragile</a> in pricey ZIP codes. Financial planners say the findings are a reminder to weigh state taxes, health-care access and, above all, living costs before <a href="https://www.benzinga.com/real-estate/24/09/40728965/can-you-guess-which-state-was-just-ranked-as-1-best-place-to-retire-hint-its-not-florida">picking a retirement haven</a>.
Image via Shutterstock
Read next: <a href="https://www.benzinga.com/personal-finance/25/04/44969001/65-year-old-with-110k-saved-asks-if-he-can-retire-in-7-years-dave-ramsey-says-you-have-no-money-and-tells-him-to-stop-401k-contributions">65-Year-Old With $110K Saved Asks If He Can Retire in 7 Years — Dave Ramsey Says &#8216;You Have No Money&#8217; and Tells Him to Stop 401(k) Contributions</a>

Personal Finance

General

$2 Million Nest Egg Could Buy You Seven Decades — Or Barely Two: Best And Worst States For Retirement Longevity

Barrington Research analyst Vincent Colicchio maintains WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) with a Outperform and maintains $75 price target.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on WNS (Hldgs), Maintains $75 Price Target

Piper Sandler analyst Clarke Jeffries maintains Tyler Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) with a Overweight and lowers the price target from $747 to $708.

Piper Sandler Maintains Overweight on Tyler Technologies, Lowers Price Target to $708

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced that the first patient has been administered both the first protein dose and the 177Lu-DOTA imaging dose in its Phase 1 clinical trial evaluating the Company's Self-Assembly and Disassembly ("SADA") Pre-targeted Radioimmunotherapy ("PRIT") platform for the treatment of patients with relapsed or refractory non-Hodgkin Lymphoma (r/r NHL). This Phase 1 trial (Trial 1201) is a dose-escalation, open-label, single-arm, multi-center trial investigating the safety and tolerability of the CD38-SADA: 177Lu-DOTA Drug Complex.
Trial 1201 is designed to investigate the pre-targeted delivery of the CD38-SADA protein that binds with high affinity to lymphoma cells, followed by the administration of a radioactive 177Lu-DOTA payload to selectively target the tumor-bound CD38-SADA molecules while minimizing radiation to normal tissues. Part A of the trial is CD38-SADA dose escalation with fixed 177Lu-DOTA payload doses to explore the optimal CD38-SADA protein dose and interval between the SADA protein administration and the payload. The primary endpoints of Part A include tumor imaging and occurrence of dose limiting toxicities in the dose limiting toxicities (DLT) evaluation period.
 &nbsp;
 &nbsp;

YMAB

Y-mAbs Says First Patient Administered First Protein Dose And 177Lu-DOTA Imaging Dose In Phase 1 Clinical Trial Evaluating CD38-SADA Pre-Targeted Radioimmunotherapy In r/r NHL

HC Wainwright &amp; Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) with a Buy and maintains $72 price target.

Reiteration

HALO

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $72 Price Target

Barrington Research analyst Gary Prestopino maintains Stoneridge (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRI#NYSE">SRI</a>) with a Outperform and maintains $16 price target.

Barrington Research Maintains Outperform on Stoneridge, Maintains $16 Price Target

Biotech

Health Care

PLRZ

Polyrizon Announced Preliminary Safety Study For A Formulation Of Its PL-14 Allergy Blocker, Conducted On Fully Differentiated Human Nasal Tissue Using The Mucilair Model, The Study Demonstrated Strong Local Tolerability

Barrington Research analyst Gary Prestopino maintains Standex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SXI#NYSE">SXI</a>) with a Outperform and maintains $220 price target.

Barrington Research Maintains Outperform on Standex International, Maintains $220 Price Target

Barrington Research analyst Gary Prestopino maintains Kadant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KAI#NYSE">KAI</a>) with a Outperform and maintains $410 price target.

Barrington Research Maintains Outperform on Kadant, Maintains $410 Price Target

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>) with a Buy and maintains $5 price target.

TNYA

HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target

Barrington Research analyst Alexander Paris maintains H&amp;R Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) with a Outperform and maintains $70 price target.

Barrington Research Maintains Outperform on H&R Block, Maintains $70 Price Target

SHANGHAI, China, April 25, 2025 (GLOBE NEWSWIRE) -- Pony AI Inc. ("Pony.ai" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>), a global leader in achieving large-scale commercialization of autonomous mobility, announced a strategic partnership with Tencent Cloud and Smart Industries Group ("CSIG", or the "Tencent Cloud"), the cloud business of Tencent Holding Limited (HKEX: 00700, "Tencent"), a world-leading Internet and technology company in China, to jointly advance autonomous driving technology and accelerate the commercialization of Robotaxi services. This partnership will amplify Pony.ai's cutting-edge autonomous driving technology by leveraging Tencent's ecosystem — including Weixin,&nbsp;Tencent Maps and its robust cloud computing, big data and AI infrastructure. It marks a significant step forward for Pony.ai's ongoing journey toward large-scale commercialization.
 &nbsp;

PONY

Pony AI Partners With Tencent Cloud And Smart Industries Group To Jointly Advance Autonomous Driving Technology, Accelerate Commercialization Of Robotaxi Services

Saia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) reported quarterly earnings of $1.86 per share which missed the analyst consensus estimate of $2.77 by 32.85 percent. This is a 44.97 percent decrease over earnings of $3.38 per share from the same period last year. The company reported quarterly sales of $787.58 million which missed the analyst consensus estimate of $810.94 million by 2.88 percent. This is a 4.35 percent increase over sales of $754.77 million the same period last year.

Earnings Misses

SAIA

Saia Q1 EPS $1.86 Misses $2.77 Estimate, Sales $787.58M Miss $810.94M Estimate

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) affirms FY2025 GAAP EPS guidance from $24.05-$25.85 to $24.05-$25.85 vs $24.97 analyst estimate. Affirms FY2025 sales outlook from $72.80 billion-$75.80 billion to $72.80 billion-$75.80 billion vs $74.63 billion estimate.

Guidance

HCA Healthcare Affirms FY2025 GAAP EPS Guidance of $24.05-$25.85 vs $24.97 Est; Affirms FY2025 Sales Guidance of $72.80B-$75.80B vs $74.63B Est

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) affirms FY2025 sales outlook from $3.23 billion-$3.43 billion to $3.23 billion-$3.43 billion vs $3.34 billion estimate.

PHIN

Phinia Affirms FY2025 Sales Guidance of $3.23B-$3.43B vs $3.34B Est

Phinia (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHIN#NYSE">PHIN</a>) reported quarterly earnings of $0.94 per share which missed the analyst consensus estimate of $1.01 by 6.93 percent. This is a 12.96 percent decrease over earnings of $1.08 per share from the same period last year. The company reported quarterly sales of $796.00 million which missed the analyst consensus estimate of $814.39 million by 2.26 percent. This is a 7.76 percent decrease over sales of $863.00 million the same period last year.

Phinia Q1 Adj. EPS $0.94 Misses $1.01 Estimate, Sales $796.00M Miss $814.39M Estimate

HCA Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>) reported quarterly earnings of $6.45 per share which beat the analyst consensus estimate of $5.76 by 11.98 percent. This is a 20.34 percent increase over earnings of $5.36 per share from the same period last year. The company reported quarterly sales of $18.32 billion which beat the analyst consensus estimate of $18.26 billion by 0.35 percent. This is a 5.66 percent increase over sales of $17.34 billion the same period last year.

HCA Healthcare Q1 Adj. EPS $6.45 Beats $5.76 Estimate, Sales $18.32B Beat $18.26B Estimate

Needham analyst Scott Berg reiterates SPS Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPSC#NASDAQ">SPSC</a>) with a Buy and maintains $210 price target.

SPSC

Needham Reiterates Buy on SPS Commerce, Maintains $210 Price Target

Press Releases

CORRECTION FROM SOURCE: Greenlane Appoints Rob Shields as Chief Growth Officer

Greenlane Signs New Exclusive U.S. Distribution Agreement with Green Gruff USA Inc.

Greenlane Regains Full Compliance with Nasdaq Continued Listing Rules

Greenlane Holdings, Inc. Announces $25.0 Million Private Placement Priced at the Market Under Nasdaq Rules

Greenlane Holdings, Inc. Announces Closing of $25.0 Million Private Placement

Aegis Capital Corp. acted as Exclusive Placement Agent on a $25.0 Million Private Placement Priced At-the-Market for Greenlane Holdings, Inc. (NASDAQ:GNLN)

Comments

Greenlane Hldgs

ニュース

最新ニュース Greenlane Hldgs (NASDAQ:GNLN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル